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S344 Poster Session IItransplantation (HSCT) remains one of the best options to cure T-
ALL. However, many patients cannot find an HLA-matched do-
nor. Our institute established a new protocol for haplo-identical
HSCT. Busulfan, cyclophosphamide, cytosine arabinoside and
methyl CCNU plus anti-thymocyte globulin was used for condi-
tioning therapy. Seventy-two patients diagnosed with T-ALL un-
derwent transplantation from haplo-identical donor family
members. Risk factor analysis are summarised in Table 1. The in-
cidence rates of grades II to IV acute graft versus host disease
(aGVHD) and of grades III and IV aGVHD were 49%612%
and 19%612%, respectively. The cumulative incidence rate for
chronic GVHD (cGVHD) at two years after HSCT was 41%6
12%. After a median follow-up of 12 months, fifteen patients had
relapsed, fourteen died from relapse, and forty-one patients were
still alive without disease recurrence. The probability of leuke-
mia-free survival (LFS) was 44.2%67.4% at three years.Patients
transplanted during their first complete remission (CR1 had a lower
relapse rate (18.8% vs. 37.5%, p 5 0.049, with a RR 5 0.247, p 5
0.007), a lower non-relapse mortality (NRM) rate (16.6% vs.
50.0%, p 5 0.046, with a RR 5 0.279, p 5 0.024) and better
LFS (54.8% vs 12.5%, p 5 0.001, with a RR 5 0.315, p 5
0.004) compared with patients transplanted beyond CR1. This
study confirmed that haplo-identical/mismatched HSCT could be
an alternative treatment choice for T-ALL.377
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Allogeneic stem cell transplantation (allo-SCT) is considered
the best post-remission therapy for patients with Ph+ALL. How-
ever, the application of this procedure is limited by the availabil-
ity of suitable HLA-compatible donors. Umbilical cord blood
transplantation (UCBT) from unrelated donors has emerged as
an alternative approach for patients lacking an HLA-matched
donor. This study compares the clinical outcome of 36 adults
with Ph+ALL who received either UCBT from unrelated donors
(n 5 25) or bone marrow or peripheral blood stem cell trans-
plantation (BMT/PSCT) from HLA-matched sibling donors
(n 5 11) at a single institution. From June 1999 to August
2010, all consecutive patients with Ph+ALL, except one who re-
ceived total body irradiation, received busulfan, thiotepa, and cy-
clophosphamide or fludarabine as myeloablative conditioning
regimen. Antithymocyte globulin was added in UCBT patients.
All patients received cyclosporine as graft-versus-host disease
prophylaxis, combined prednisone or mycophenolate mofetil in
UCBT or methotrexate in matched-sibling allo-SCT. Median
age was 33 years (range, 16-54) and 21 (58%) were males. At
time of transplantation, 28 (78%), 3 (8%) and 5 (14%) were in
first complete remission (CR), second or further CR and more
advanced phase of the disease, respectively. Patient and disease
characteristics were similar in both groups. Except for one pa-
tient undergoing UCBT that experienced primary graft failure,
all remaining patients engrafted. Myeloid engraftment was faster
in BMT/PSCT than UCBT (median 12 days vs 20 days; p\
0.01). With a median follow-up of surviving patients of 41
months (range 15-114), the 4-year CI of NRM for UCBT and
BMT/PSCT recipients was 36% and 9%, respectively (p 5
0.1), and the CI of relapse 22% and 64%, respectively (p 5
0.15). Disease-free survival at 4 years was 42% in UCBT and
27% in matched-sibling allo-SCT recipients; (p 5 0.6). Our
data suggest that for patients with Ph+ALL, UCBT from unre-
lated donors is a reasonable approach with efficacy similar to
that of BMT/PSCT from HLA-identical sibling.378
ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED
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Weprospectively assess, in pts over 55years, eligible for anmatched
sibling Allo-SCT, the impact of a RIC with Fludarabine (30 mg/m2/
day (D-5 toD-1)), IVBusulfan (0.8mg/kg x 4/day (D-4 toD-3)) and r-
ATG (2.5 mg/kg/day (D-2 to D-1). Eventually, from 03/07 to 06/10,
82 pts have been included, of which 79 have been transplanted. Me-
dian follow-up is 24 months (10-50). All grafts were PBSC from
aHLA identical sibling. CSA (2mg/kg) was started on day -2.Median
age is 60 (55-70). Karnofsky score was 90 (60-90). Diagnoses: AML5
32;MDS5 13; ALL5 6; NHL5 10;MM5 13; Others5 5); 54 pts
were in CR (CR15 31; CR25 15; CR.25 8), 22 in PR or SD and 3
inPDafter amedianof 2 (1-7) lines of chemotherapy.All pts engrafted
and 46 presented with aGVHD (G1 n5 32; G2: n5 7; G3-4: n5 6)
for a 17% (10-23) cumulative incidence of G$ 2 aGVHD. A total of
47 pts had cGVHD (Limited: N5 28; extensive: N5 19) at a median
of 4.5 months (3-21) for a one year overall and extensive cumulative
incidence of 57% (46-68) and 34% (25-45) respectively. 12 pts died
from NRM. The 6 month and overall cumulative incidences of
NRM were 5% (0-10) and 16% (9-23) respectively. Karnofsky score
was not predictive ofNRM. 25 pts relapsed at a median of 4.2months
(0.8-12) for a cumulative incidence of 32% (23-42). Relapse incidence
differed according to disease pre-transplant status (9 of 46 CR1/CR2
vs. 16 of 33 beyond CR2 pts; p 5 0.008). Three year overall and dis-
ease-free survival probabilities were 79% (67-87) and 59% (45-71) re-
spectively. Considering the CR1 AML population (N5 21), median
age was 61 years (56-70) and probabilities of NRM, relapse, OS and
LFS were 14% (IC95 5 0-27), 14% (IC95 5 2-26), 72% (IC95 5
47-86) and 67 % (IC955 43-83) respectively. Economic data cover-
ing transplant and first 18 month post-transplant periods have been
prospectively collected and are under analysis. HRQL (Health Re-
lated Quality of Life) was assessed over a 1-year period with the
EORTC QLQ-C30 questionnaire (Days -7, +80, +180, +360). The
lowest functioning scores and highest symptom scores were experi-
enced 80 days after transplantation. Thereafter the level of function-
ing and level of symptoms returned to baseline levels, which is
reassuring in this population. Taking account patient characteristics,
results confirm that Allo-SCT after RIC is a valid option in this pop-
ulation, that RI. Further refining of this association, by cautious tun-
ing of the IV Busulfan dose, is under process in our program.379
FLUDARABINE AND CYCLOPHOSPHAMIDE PROVIDE A NON-MYELOA-
BLATIVE ALTERNATIVE CONDITIONING REGIMEN WITH LOW TRANS-
PLANT-RELATED MORTALITY AND CONTROL OF HIGH RISK DISEASE
Paplham, P., Hahn, T., Brown, K., Syta, M., Dubel, K., Lipka, P.,
McCarthy, P. Roswell Park Cancer Institute, Buffalo, NY
Myeloablative allogeneic hematopoietic cell transplant (MAT)
regimens are associated with significant transplant-related mortality
(TRM). Non-myeloablative (NMAT) regimens have a curative po-
tential for patients who would not be considered MAT candidates
due to factors such as older age, co-morbidities, prior failed MAT
or poor Karnofsky Performance Score (KPS). We performed a pro-
spective phase II clinical trial of a NMAT regimen with the objec-
tives to determine TRM, progression-free (PFS) and overall
survival (OS). Forty patients were enrolled April 2002 - December
2008 at a single center and received cyclophosphamide 50 mg/kg/d
